The life sciences business developing compounds to tackle obesity, high cholesterol and diabetes has this week announced that it has registered an additional five proprietary microbial strains (now a total of eight) under the Budapest treaty. The five strains have been identified as having the potential to generate novel oligosaccharides (carbohydrates that consist of a small number of sugars). As OptiBiotix advances its programmes towards commercialisation it is vital that its know-how, micr
08 Oct 2015
IP asset base continues to strengthen
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
IP asset base continues to strengthen
OptiBiotix Health PLC (OPTI:LON) | 18.0 0 0.0% | Mkt Cap: 17.6m
- Published:
08 Oct 2015 -
Author:
Derren Nathan -
Pages:
7
The life sciences business developing compounds to tackle obesity, high cholesterol and diabetes has this week announced that it has registered an additional five proprietary microbial strains (now a total of eight) under the Budapest treaty. The five strains have been identified as having the potential to generate novel oligosaccharides (carbohydrates that consist of a small number of sugars). As OptiBiotix advances its programmes towards commercialisation it is vital that its know-how, micr